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Background: Pyrethroid pesticides cause abnormalities in the dopamine system and produce an ADHD phenotype
in animal models, with effects accentuated in males versus females. However, data regarding behavioral effects of
pyrethroid exposure in children is limited. We examined the association between pyrethroid pesticide exposure and
ADHD in a nationally representative sample of US children, and tested whether this association differs by sex.
Methods: Data are from 8–15 year old participants (N = 687) in the 2001–2002 National Health and Nutrition Examination
Survey. Exposure was assessed using concurrent urinary levels of the pyrethroid metabolite 3-phenoxybenzoic acid (3-PBA).
ADHD was defined by either meeting Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition criteria on the
Diagnostic Interview Schedule for Children (DISC) or caregiver report of a prior diagnosis. ADHD symptom counts were
determined via the DISC. Multivariable logistic regression examined the link between pyrethroid exposure and ADHD, and
poisson regression investigated the link between exposure and ADHD symptom counts.
Results: Children with urinary 3-PBA above the limit of detection (LOD) were twice as likely to have ADHD compared
with those below the LOD (adjusted odds ratio [aOR] 2.42; 95 % confidence interval [CI] 1.06, 5.57). Hyperactive-impulsive
symptoms increased by 50 % for every 10-fold increase in 3-PBA levels (adjusted count ratio 1.50; 95 % CI 1.03, 2.19);
effects on inattention were not significant. We observed possible sex-specific effects: pyrethroid biomarkers were
associated with increased odds of an ADHD diagnosis and number of ADHD symptoms for boys but not girls.
Conclusions: We found an association between increasing pyrethroid pesticide exposure and ADHD which may
be stronger for hyperactive-impulsive symptoms compared to inattention and in boys compared to girls. Given
the growing use of pyrethroid pesticides, these results may be of considerable public health import.
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Attention Deficit Hyperactivity Disorder (ADHD), the
most common neurobehavioral disorder in children
[1, 2], is associated with significant impairments in aca-
demic, social, and occupational functioning [3]. ADHD
is a heritable disorder, but environmental and other* Correspondence: tanya.froehlich@cchmc.org
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The link between ADHD and environmental toxins, in-
cluding organophosphate pesticides, is growing [5–7].
Due to increasing concern about their adverse health
consequences, the U.S. Environmental Protection Agency
banned the two most commonly used organophosphate
pesticides from residential use in 2000–2001, leading to
escalating use of an alternative class of pesticides – the
pyrethroids [8]. Pyrethroids are now the most commonly
used pesticides for residential pest control and public
health purposes (including control of vector-bornen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[9, 10], with U.S. biomonitoring studies confirming wide-
spread exposure to one or more pyrethroids [11].
Although pyrethroid pesticides are often considered a
“safer” choice because they are generally not as acutely
toxic as organophosphates [12], animal studies indicate
that exposure to pyrethroids may not be benign. Specif-
ically, increased dopamine transporter (DAT) expression
[13] and elevated DAT-mediated dopamine uptake [14,
15] were detected in mice exposed to the pyrethroids
deltamethrin and permethrin. Given that elevated DAT
expression has been observed in some studies of individ-
uals with ADHD [16] and that a dopamine deficit has
been hypothesized to be central to the neurophysiology
of ADHD [17], it is plausible that pyrethroid exposure
could elevate the risk for developing ADHD. Indeed, nu-
merous studies have found that rodents exposed to pyre-
throids during a critical period of brain development
have increased locomotor activity during adulthood
[18–23]. In addition, this animal research indicates that
there may be a heightened vulnerability to the effects of
pyrethroid exposure on hyperactivity, impulsivity, and
dopamine transporter levels in male compared to female
mice [23, 24].
In prior publications, the behavioral effects of pyreth-
roid exposure in children have received little attention.
Oulhote et al. found that postnatal pyrethroid exposure
was associated with general behavioral difficulties [25],
but, contrary to the animal study findings, this associ-
ation was more pronounced in girls compared to boys.
[25] Quiros-Alcala et al. did not observe a significant
relationship between current pyrethroid exposure and
parent report of a prior ADHD diagnosis [26]. However,
no previous publications have utilized an ADHD-specific
diagnostic measure or examined ADHD symptoms di-
mensionally when evaluating the association between
pyrethroid biomarkers and ADHD.
We hypothesized that current pyrethroid pesticide expos-
ure would be associated with a positive ADHD diagnostic
status and an increased number of ADHD symptoms in a
nationally representative sample of U.S. children when as-
certainment included an ADHD-specific diagnostic meas-
ure. In addition, we sought to test whether the effects of
pyrethroids differed in boys compared to girls, given that




Our study sample consisted of subjects that participated
in the National Health and Nutrition Examination Survey
(NHANES). The NHANES is a multi-stage probability
sample survey that assesses the health and nutritional sta-
tus of the US population. We used data from NHANES2001–2002 for 8 to 15 year old children, which was the
only NHANES cycle that included a structured diagnostic
interview of children’s ADHD symptoms, concurrent pyr-
ethroid pesticide biomarkers, and relevant covariates [27].
Pyrethroid pesticide exposure measurements were col-
lected in a random sample of 50 % of the 8 to 11 year olds
and 33 % of the 12 to 15 year olds who participated in the
2001–2002 data collection. Data from the diagnostic inter-
view of ADHD symptoms was available for 84 % of chil-
dren. Of the 2,028 8 to 15 year old children participating
in the NHANES, data from 687 children (34 % of total)
was available for these analyses. Children who were in-
cluded in these analyses did not differ from children who
were not included on age, sex, race/ethnicity, income,
health insurance status, prenatal tobacco exposure, birth
weight, current tobacco exposure, blood lead level, urinary
organophosphate metabolite levels, caregiver report of a
prior ADHD diagnosis, ADHD diagnostic status as deter-
mined by DSM-IV criteria, or ADHD defined by caregiver
report and/or DSM-IV criteria (See Table 1).
ADHD measurement
Our primary outcome was ADHD, defined as meeting
DSM-IV criteria for ADHD and/or having a caregiver-
reported prior diagnosis of ADHD. The National Insti-
tute of Mental Health Diagnostic Interview Schedule
for Children (DISC) was used to assess for DSM-IV-
defined ADHD based on standardized algorithms as
per prior studies [1]. The DISC is a structured diagnostic
interview instrument designed for use in epidemiological
and clinical studies, with reliable versions available in
English [28] and Spanish [29, 30]. Caregivers completed
the ADHD DISC module two to four weeks after the
child’s NHANES Mobile Examination Center evaluation,
providing information about the child’s ADHD symptoms,
age of onset, symptom pervasiveness, and related im-
pairments over the prior twelve months. In our sam-
ple, participants’ Inattentive symptom counts had a
mean (SD) = 1.3 (2.4), median = 0, and range = 0-9;
Hyperactive-Impulsive symptom counts had a mean
(SD) = 1.0 (2.0), median = 0, and range = 0-9. Given
that over half of children diagnosed with ADHD
during earlier childhood continue to have significant
impairment but no longer meet formal diagnostic cri-
teria during adolescence [31, 32], and that successful
treatment with ADHD medications can reduce symptoms
below the diagnostic threshold, our primary ADHD case
definition also included prior caregiver report of an
ADHD diagnosis. To determine whether a child had a
prior ADHD diagnosis, caregivers were asked, “Has a
doctor or health professional ever told you that [child’s
name] had attention deficit disorder?” during an NHANES
interview module that occurred before the DISC
interview.
Table 1 Comparison of characteristics for participants age 8-15 years not included and included in sample
Not Included Included
Characteristic N with Characteristica %a Overall Na N with Characteristica %a Overall Na
Age 8-11 years 490 46.8 1341 307 46.5 687
Male gender 661 51.3 1341 323 52.9 687
Race/ethnicity
African American 451 15.4 1341 210 13.0 687
Mexican American 386 11.0 1341 205 11.1 687
Other race/ethnicity 111 14.2 1341 56 12.5 687
White, non-Hispanic 393 59.4 1341 216 63.4 687
Caregiver report of ADHD 96 9.7 1139 66 10.8 684
DSM-IV Defined ADHD 75 9.9 966 55 9.6 667
ADHD by DSM-IV Criteria and/or Caregiver report 137 17.8 980 93 14.6 687
Poverty-Income Ratio
<1.00 370 20.9 1260 203 20.7 664
1.00-1.85 318 22.7 1260 155 20.2 664
>1.85-3.00 231 20.0 1260 125 22.0 664
>3.00 341 36.4 1260 181 37.1 664
Reported health insurance 1109 88.0 1325 564 83.6 681
Reported prenatal tobacco exposure 203 17.2 1325 92 18.1 677
Birth weight <2.5 kg 130 8.2 1322 50 5.9 682
Reported current household tobacco smoke exposure 298 23.2 1326 145 22.7 683
Urinary 3-PBA < LOD 29 23.2 148 131 21.2 687
Abbreviations: ADHD, Attention-Deficit/Hyperactivity Disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; SE, standard error;
LOD, limit of detection; 3-PBA, 3-phenoxybenzoic acid
aN reflects actual sample size, % is weighted to reflect national prevalence estimates
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Our primary exposure was urinary levels of 3-
phenoxybenzoic acid (3-PBA). 3-PBA is a metabolite of
several pyrethroid pesticides, and is the most frequently
detected pyrethroid metabolite in studies of children that
assess pyrethroid exposure from multiple sources (includ-
ing food and within the home) [11]. Urinary measures of
3-PBA were determined using high-performance liquid
chromatography/electrospray chemical ionization/tandem
mass spectrometry [27, 33]. The limit of detection for 3-
PBA was 0.1 μg/l.
Covariates
We included potential confounders that might bias the
association between pyrethroid pesticide biomarkers and
ADHD in the statistical models. These were chosen
based on their association with ADHD in the prior lit-
erature, and included child sex [34], household income
to poverty line ratio [PIR] (in quintiles) [1], age [34],
race/ethnicity (African-American, Mexican-American,
Non-Hispanic white, or Other race) [1], health insurance
status (yes or no) [35], prenatal tobacco exposure (yes or
no) [36, 37], blood lead level [36, 37] (log10-transformed),
and urinary organophosphate pesticide metabolite level [6](3 dimethyl alkylphosphate [DMAP], log10-transformed).
Race was identified by the caregiver. The Other race cat-
egory (N = 56) included both non-Mexican Hispanic indi-
viduals as well as those individuals who identified as “other
race” because of the small number of participants identified
in either group. Health insurance status was reported by
the caregivers. Models were also adjusted for urinary
creatinine levels (as recommended by Barr et al. [38]) to
account for urine dilution.
Analyses
This study was determined to be exempt from review by
the institutional review board (IRB) at Cincinnati Chil-
dren’s Hospital Medical Center (Study #: 2011-1686).
Descriptive statistics on the prevalence of ADHD [DSM-
IV-defined ADHD and/or reported prior diagnosis] were
tabulated for those who had urinary 3-PBA levels below
and above the limit of detection.
The association between ADHD and urinary 3-PBA
(levels below versus above the limit of detection) was
analyzed via logistic regression, adjusting for potential
confounders. Logistic regression was used to examine
the association between continuous urinary 3-PBA levels
(log10-transformed due to skewed distributions) and
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the consistency of pyrethroid pesticide associations, add-
itional analyses, available in Additional file 1: Table S1
and Additional file 2: Table S2, were conducted to exam-
ine associations with the individual components of our
ADHD case definition separately [i.e., 1) meeting DSM-
IV criteria for ADHD, 2) having a caregiver report of a
prior ADHD diagnosis] but are less precise due to
smaller cell sizes.
We used Poisson regression to assess the relationship
between urinary 3-PBA levels and the number of in-
attentive and hyperactive symptoms endorsed as being
present ‘often’ in at least two settings, adjusting for po-
tential confounders. The Poisson distribution accounts
for the skewed and count nature of these data. Analyses
investigated urinary 3-PBA levels as both a dichotomous
predictor (levels below versus above the limit of detection)
and a continuous predictor (log10-transformed levels). For
each model, adjusted count ratios were calculated to de-
termine the mean percent increase in symptom counts
beyond that of the reference group for each stratum of
the 3-PBA variables.
To examine the dose–response relationship between
continuous 3-PBA levels and ADHD, we fit 3-knot re-
stricted cubic polynomial splines (with knots at the 10th,
50th, and 90th percentiles of log10-transformed urinary 3-
PBA levels), adjusting for potential confounders. Ana-
lyses using restricted cubic polynomial splines provide
flexibility in modeling the relationship between the ex-
posure and the outcome, and avoid assumptions about
model linearity [39].
Finally, due to evidence that the neurobehavioral ef-
fects of pyrethroid pesticide exposure may differ in
males and females, we conducted stratified analyses by
child gender and formally tested effect measure modifi-
cation using a sex*3-PBA interaction term in our logistic
regression models.
Analyses were performed using SUDAAN (version 9,
Research Triangle Institute, Research Triangle Park, NC)
to account for NHANES’ complex survey design. Sample
weights were applied according to National Center for
Health Statistics guidelines to generate all estimates.
Results
Descriptive statistics
Among 8 to 15 year old participants (n = 687), 14.6 %
(95 % CI, 10.6-19.8) met our primary ADHD definition:
meeting DSM-IV criteria for ADHD and/or having a
prior ADHD diagnosis. Table 1 lists separate rates of
participants 1) meeting DSM-IV criteria for ADHD and
2) having a prior reported ADHD diagnosis. The weighted
mean urinary 3-PBA level in our sample was 1.14 μg/L
(Standard Error ±0.22), and the 10th, 50th, and 90th per-
centiles were 0.07, 0.29, and 1.94 μg/L respectively.Urinary 3-PBA levels were below the limit of detection
(LOD) in 21.1 % (N = 131) of participants.
Associations between pyrethroid pesticides on ADHD
In bivariate analyses, the prevalence of ADHD was
higher in those who had detectable urinary pyrethroid
pesticide levels than in those with non-detectable levels
(16.0 % vs 9.6 %, p = 0.03). After confounder adjustment,
children who had detectable urinary 3-PBA levels were
more than twice as likely to have ADHD compared with
those who had non-detectable levels (adjusted odds ratio
[aOR] 2.42; 95 % confidence interval [CI] 1.06, 5.57).
Each 10-fold increase in urinary 3-PBA level (corre-
sponding approximately to a shift of 3-PBA levels from
the 20th to 80th percentile) was associated with a 57 %
increase in the prevalence of ADHD (aOR 1.57; 95 % CI
0.88, 2.78).
In sex-stratified analyses, we found stronger associations
between urinary 3-PBA levels and ADHD in boys com-
pared to girls. Boys with detectable urinary 3-PBA levels
were almost three times as likely to have ADHD com-
pared with boys who had non-detectable levels (aOR 2.95;
95 % CI 1.07, 8.08), while the effects of 3-PBA levels in
girls were smaller (aOR for girls with detectable vs non-
detectable levels: 1.54; 95 % CI 0.32, 7.33). However, the
effect modification (3-PBA*sex interaction term) p-value
was not statistically significant (p = 0.68). Modeling
urinary 3-PBA levels as a logarithmically-transformed
continuous variable was more suggestive of sex-specific
effects (3-PBA*sex interaction term p = 0.09). For boys,
a 10-fold increase in urinary 3-PBA level was associated
with a 43 % increase in the prevalence of having either
DSM-IV-defined or parent-reported ADHD (aOR 1.43;
95 % CI 1.05, 1.94), while for girls this association was
null (aOR 0.91; 95 % CI 0.57, 1.43).
Associations between pyrethroid pesticides and ADHD
symptom counts
Higher 3-PBA levels were associated with an increasing
number of hyperactive-impulsive symptoms. Hyperactive-
impulsive symptom counts were 77 % higher for children
with detectable 3-PBA levels compared to children with
non-detectable levels (adjusted count ratio [aCR] 1.77;
95 % CI 0.95, 3.30) (Table 2). A similar relationship was
observed when 3-PBA levels were modeled as a continu-
ous log10-transformed variable: every 10-fold increase in
urinary 3-PBA levels was associated with a 50 % increase
in hyperactive-impulsive symptoms (aCR 1.50; 95 % CI
1.03, 2.19). No significant or borderline significant associa-
tions were observed between inattentive symptom counts
and 3-PBA levels (modeled as either a dichotomous or
continuous variable) in whole sample models (Table 2).
Sex-stratified analyses revealed significant associations
between 3-PBA levels and ADHD symptom counts in
Table 2 Adjusted count ratiosa for association of urinary 3-PBA





ACR (95 % CI) ACR (95 % CI)
Urinary 3-PBA Level≥ LOD
Overall 1.26 (0.75, 2.12) 1.77 (0.95, 3.30)
Boys 1.61 (0.92, 2.80) 2.49 (1.17, 5.27)
Girls 0.89 (0.44, 1.81) 1.01 (0.51, 2.00)
Log10-transformed Urinary 3-PBA
Overall 1.21 (0.83, 1.78) 1.50 (1.03, 2.19)
Boys 1.49 (1.05, 2.12) 1.57 (1.05, 2.34)
Girls 1.00 (0.58, 1.71) 1.51 (0.88, 2.60)
Abbreviations: 3-PBA, 3-phenoxybenzoic acid; ACR, Adjusted Count Ratios; LOD,
limit of detection
aAdjusted for child’s age, race/ethnicity, income, health insurance status,
prenatal tobacco exposure, blood lead level (log10-transformed), urinary
organophosphate metabolite level (log10-transformed), and urinary creatinine
level. Overall models also adjust for sex
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toms were more than double in boys with detectable urin-
ary 3-PBA levels compared to those with non-detectable
levels (aCR 2.49; 95 % CI 1.17, 5.27). When 3-PBA levels
were modeled as a log10-transformed continuous variable,
each 10-fold increase in urinary 3-PBA levels was associ-
ated with a 49 % increase in inattentive symptom counts
(aCR 1.49; 95 % CI 1.05, 2.12) and a 57 % increase in
hyperactive-impulsive symptom counts (aCR 1.57; 95 %
CI 1.05, 2.34) among boys.
Spline analyses
Our restricted cubic polynomial spline analysis in the
overall sample suggested a steeper increase in the log-
odds of ADHD at the lower 3-PBA levels, with the asso-
ciation between the log-odds of ADHD and pyrethroid
metabolite levels remaining elevated but plateauing at
higher 3-PBA levels (Fig. 1). Sex-stratified spline analyses
demonstrated sex-specific effects of pyrethroid exposure.
In boys, a curvilinear dose–response relationship was
observed between 3-PBA levels and increasing log-odds
of ADHD with no plateau level observed (Fig. 2). Spline
analysis in girls revealed a relatively flat relationship be-
tween 3-PBA exposure levels and ADHD such that in-
creasing pyrethroid metabolite levels did not appreciably
increase log-odds of ADHD (Fig. 3). The likelihood ratio
test for all 3 splines (overall sample, boys only, and girls
only) had p < 0.01, indicating goodness of fit for all three
models.
Discussion
Higher pyrethroid exposure was associated with an ele-
vated odds of ADHD and ADHD symptoms in this na-
tionally representative sample of US children. Ourresults are consistent with the findings in animal models
[21–24], but contrast with a study by Quiros-Alcala
et al. which also used an NHANES sample but did not
find pyrethroid exposure to be significantly associated
with ADHD [26]. This contrasting result may be due to
differences in the primary outcome definition. The
Quiros-Alcala et al. study’s primary outcomes were based
on parental report of ADHD and/or parental report of a
learning disability; they did not incorporate diagnosis of
ADHD or ADHD symptom counts as determined by the
DISC, which may represent more sensitive measures.
Additional differences between the Quiros-Alcala et al.
study and the present study include the age range (6–15
vs. 8–15 year old) and NHANES study years (1999–2002
vs. 2001–2002). Another prior study in children found an
association between postnatal pyrethroid exposure and a
general parent-report measure of behavior problems, but
did not find a specific association with hyperactivity/in-
attention [25], perhaps due to the diminished sensitivity of
their 5-item ADHD symptom measure (compared to our
DSM-IV-based measure of 18 symptoms).
Our results suggest that pyrethroid pesticide exposure
may be more strongly associated with hyperactive-
impulsive than inattentive symptoms. This is consistent
with previous animal studies demonstrating that pyreth-
roid exposure during gestation and early childhood results
in hyperactivity and impulsive-like behavior [19, 23].
Should the link between pyrethroid exposure and
hyperactivity-impulsivity in children be replicated,
these findings might represent a potential pyrethroid-
specific ADHD phenotype. Efforts to characterize etiologic-
specific ADHD phenotypes are paramount not only to
elucidating the biologic basis of ADHD: they may ultim-
ately prove useful in defining subgroups of children with
ADHD with a distinct course, comorbidity profile, and
intervention response, and thus form the basis for tar-
geted clinical and treatment efforts [4].
We observed sex-specific effects of pyrethroid exposure.
Urinary pyrethroid biomarkers were associated with in-
creased odds of an ADHD diagnosis and number of ADHD
symptoms for boys but not girls in logistic and poisson re-
gression as well as spline analyses. The sex*pyrethroid
interaction had a borderline significant p-value of 0.09
when 3-PBA was modeled as a logarithmically-transformed
continuous variable. In contrast, the interaction was not
statistically significant (p = 0.68) when 3-PBA was modeled
as a dichotomous variable [above versus below the limit of
detection]). Of note, we had reduced statistical power to
detect sex*pyrethroid interactions in dichotomous models
due to relatively small numbers of participants having the
ADHD diagnosis. This pattern suggesting possible sex-
specific effects is consistent with prior animal studies that
reported greater impulsive and hyperactive symptoms in
exposed male but not female mice [23, 24]. Further, these
Fig. 1 Spline Analysis1 Depicting Association Between 3-PBA Levels (on a Log10 Scale) and Odds of ADHD
2 in Overall Sample. Figure Legend:
1Adjusted for child’s age, sex, race/ethnicity, income, health insurance status, prenatal tobacco exposure, blood lead level (log10-transformed), urinary
organophosphate metabolite level (log10-transformed), and urinary creatinine level.
2Met Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV)-criteria for ADHD and/or had caregiver report of a prior ADHD diagnosis. Abbreviations: ADHD, Attention-Deficit/Hyperactivity
Disorder; 3-PBA, 3-phenoxybenzoic acid
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roid exposure on the brain dopamine system underlie the
observed sexual dimorphism in behavioral effects [23, 24].
It should be noted that Oulhote et al. found a stronger ad-
verse association between pyrethroid exposure and aFig. 2 Spline Analysis1 Depicting Association Between 3-PBA Levels (on a L
child’s age, race/ethnicity, income, health insurance status, prenatal tobacco e
metabolite level (log10-transformed), and urinary creatinine level.
2Met Dia
(DSM-IV)-criteria for ADHD and/or had caregiver report of a prior ADHD diagn
3-PBA, 3-phenoxybenzoic acidmeasure of total behavioral difficulties as well as oppos-
itional/conduct-specific problems in girls compared to boys
[25], although the contrast between their findings and our
own is not direct given that the sex-specific effects were ob-
served on different outcomes. Quiros-Alcala et al. did notog10 Scale) and Odds of ADHD
2 in Boys. Figure Legend: 1Adjusted for
xposure, blood lead level (log10-transformed), urinary organophosphate
gnostic and Statistical Manual of Mental Disorders, Fourth Edition
osis. Abbreviations: ADHD, Attention-Deficit/Hyperactivity Disorder;
Fig. 3 Spline Analysis1 Depicting Association Between 3-PBA Levels (on a Log10 Scale) and Odds of ADHD
2 in Girls. Figure Legend: 1Adjusted for
child’s age, race/ethnicity, income, health insurance status, prenatal tobacco exposure, blood lead level (log10-transformed), urinary organophosphate
metabolite level (log10-transformed), and urinary creatinine level.
2Met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV)-criteria for ADHD and/or had caregiver report of a prior ADHD diagnosis. Abbreviations: ADHD, Attention-Deficit/Hyperactivity Disorder;
3-PBA, 3-phenoxybenzoic acid
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and pyrethroid exposure, and it is not clear if they observed
any patterns suggesting possible sex-specific effects despite
the failure to meet thresholds for statistical significance.
Certainly, further study of sex-specific vulnerability to pyr-
ethroid exposure is warranted, given mounting evidence
that the adverse effects of some ADHD risk factors may be
accentuated or limited to certain groups [40].
Strengths of this study included our use of a nationally
representative sample of the U.S. population, such that
pyrethroid exposure levels are more likely to represent
the experience of a broad range of American children
and adolescents compared to regionally based studies. In
addition, our use of both linear and spline models
allowed us to explore more carefully the dose–response
relationship between childhood pyrethroid metabolite
levels and ADHD. Our exploration of the relationship
between pyrethroid levels and ADHD symptom counts –
in addition to ADHD diagnostic status – also enable a
fuller appreciation of the unique ADHD sub-domains that
might be more affected by pyrethroid exposure. However,
it should be noted that our Poisson models show some
evidence of over-dispersion and therefore significance
may be overestimated.
An additional limitation of our study is that pyrethroid
exposure was assessed using 3-PBA concentrations in a
single spot urine sample. Given that pyrethroids are
non-persistent and rapidly metabolized, serial measure-
ments would provide a more accurate measurement of
typical exposure [41], and are recommended in futurestudies. It should also be noted that 3-PBA detected in
child urine may not be due entirely to exposure to par-
ent pyrethroid compounds, as there may also be a minor
contribution from exposure to a byproduct formed after
pyrethroids have been hydrolyzed in the environment.
Thus, we expect that some degree of exposure misclassi-
fication occurred in this study; if it is non-differential in
nature, the tendency would be to bias toward the null,
making results an under-, rather than overestimate of
the true association [42, 43]. Subsequent studies should
also examine the association between measures of pre-
natal pyrethroid exposure (which are not available in
NHANES) and later development of ADHD, as data
from animal studies suggest that both the prenatal and
postnatal periods may represent susceptible phases for
pyrethroid neurotoxicity [18–23]. Another caveat to our
study is that we categorized urinary pyrethroid concen-
trations using the LOD as a cut point because the LOD
represents an easily interpretable threshold. However, to
guard against the assumption of constant effect sizes
without our categories, we also conducted analyses using
a restricted cubic polynomial spline, which makes no
assumptions about the shape of the dose–response rela-
tionship (see Figs. 1, 2, 3).
Misclassification of ADHD may also have played a role
in analyses for which case ascertainment included care-
giver report of the child’s prior diagnosis of ADHD, as
we cannot verify that doctors in community-based set-
tings used DSM-IV criteria when establishing ADHD
diagnoses [44]. However, our results were similar in
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based on the standardized, valid, and reliable DISC in-
strument (see Additional file 1: Table S1), although the
findings were less precise (likely due to a reduction in
cell size for this outcome), and the DISC is a caregiver-
completed measure that does not incorporate teacher re-
ports of ADHD symptoms. Furthermore, we caution that
correlation does not prove causation in this cross-
sectional study. Although we adjusted for a number of
potential confounders, we were unable to control for
genetic and other factors (e.g., diet, other aspects of the
caregiving environment) that may account for the ob-
served associations and could in fact represent reverse
causality. Nonetheless, prospective animal studies in
which case and control subjects had identical genetic
lineages and rearing environments, but differed only in
the pesticide exposure, document pyrethroid effects on
hyperactivity and impulsivity [18–23] that corroborate
our findings.
Conclusions
Our results suggest an association between childhood
urinary pyrethroid pesticide biomarkers and ADHD, par-
ticularly hyperactive-impulsive symptoms, and these as-
sociations may be stronger in boys than girls. Given the
growing use of pyrethroid pesticides and the perception
that they represent a safer pesticide alternative, these re-
sults may be of considerable public health importance.
However, replication of findings is warranted in pro-
spective, longitudinal studies with serial measurements
of pyrethroid pesticide exposure.
Additional files
Additional file 1: Table S1. Adjusted Odds Ratios1 of DSM-IV-Defined
ADHD and Caregiver-Reported ADHD by Urinary 3-PBA Status. Table
shows adjusted odds ratio of DSM-IV-defined ADHD separately from
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